United Therapeutics: TETON-1 Study for Idiopathic Pulmonary Fibrosis Offers Revenue Opportunity of $3.3 Billion!

United Therapeutics (UTHR) specializes in the treatment of rare lung diseases with its core product Tyvaso (Treprostinil). Approvals are already in place for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension related to interstitial lung disease (PH-ILD). The Phase 3 study results (TETON-1) released on March 30 for the extension of approval for idiopathic pulmonary fibrosis (IPF) significantly outperformed the results of the international TETON-2 study. With an FDA approval decision planned by the end of summer, an additional...